AbbVie JAK inhibitor reaches two primary endpoints of Phase 3 clinical trials

On October 7, 2021, AbbVie announced that its oral JAK inhibitor upadacitinib (upadacitinib, English trade name Rinvoq) has been carried out in two adult patients with axial spondylitis (axSpA).

The results of two phase 3 clinical trials showed that at week 14, whether in patients with non-radiological axial spondyloarthritis (nr-axSpA), or in patients with active ankylosing spondylitis (AS ), compared with placebo, more patients in the upatinib group achieved a 40 response of the International Spondyl Arthritis Society (ASAS)

In patients with active ankylosing spondylitis (AS)

45% of the patients in the upatinib group met the ASAS40 standard, which was significantly better than the placebo group (18%)

In addition, upatinib also reached multiple secondary endpoints of the trial.

The safety data is consistent with previous studies, and no new risks have been found

Picture source: reference [1]

In patients with active non-radiological axial spondyloarthritis

45% of the patients in the upatinib group met the ASAS40 standard, which was significantly higher than the placebo group (23%)

In addition, upatinib also reached multiple secondary endpoints of the trial.

Picture source: reference [2]

Upatinib was discovered and developed by AbbVie scientists.

Reference materials:

[1] AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis.

[2] AbbVie's upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis.

(The original text has been deleted)